CARE Ratings Limited (CARERATING) Fair Value & Analysis
Financial Services · IN · Market cap ₹49.7B
Fair value as of: Jun 29, 2026
Analysis
CARE Ratings Limited (CARERATING) currently trades at ₹1,653, while our model-based Fair Value estimate is ₹740.28 — implying the stock looks roughly 55.2% overvalued today. We read business quality at 95/100 (high quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
CARE Ratings Limited, a credit rating agency, provides various rating and related services in India and internationally. It offers rating services for bank loan, debt instrument, bonds, long and short term instruments, InvITs, resolution plan, and non-convertible debentures; CDs for banks, bonds, mutual funds, and hybrid instruments; bank debt and capital market instruments, such as commercial papers, corporate bonds and debentures, and structured credit; structured finance ratings; insurance ratings; recovery ratings; issuer ratings; ratings of REITs; public finance; and monitoring agency for equity capital. The company was formerly known as Credit Analysis and Research Limited and changed its name to CARE Ratings Limited in June 2017. CARE Ratings Limited was incorporated in 1993 and is headquartered in Mumbai, India.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is CARE Ratings Limited (CARERATING) undervalued?
What is the fair value of CARERATING?
What is the quality score of CARERATING?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.